Connect your AI

Tandem Diabetes Care TNDM Work in process

Work in process at other companies

AbbottABT

$994M+11.7%

OmnicellOMCL

$1.64M-27.2%

ICU MedicalICUI

$48.14M+8.4%

CareDxCDNA

$3.61M-24.9%

InsuletPODD

——

MedtronicMDT

——

Other financials

Income statement

Revenue$247.2M+5.5%

Gross profit$136.8M+15.5%

Operating income-$17.4M+85.6%

Net income-$20.4M+84.4%

EPS (diluted)-$0.30+84.8%

Balance sheet

Cash & equivalents$179.3M+235%

Total debt$734.7M+49.0%

Total equity$132.4M-14.7%

Total assets$1.2B+25.1%

Cash flow

Operating cash flow$11.1M+160%

CapEx$6.3M+111%

Free cash flow$4.8M+123%

Valuation

Market cap$1.08B-19.8%

Enterprise value$1.64B-8.5%

P/S1.1×-0.3×

Profitability

Gross margin54.9%+2.7pp

Operating margin-8.2%-2.9pp

Net margin-9.2%-3.1pp

FCF margin-0.8%-0.4pp

Returns & leverage

Return on equity-65.7%-14.7pp

Debt / equity5.5×+2.4×

Current ratio3.6×+1.3×

Where this comes from

Reported directly by Tandem Diabetes Care in its filing.

Tagged under the XBRL concept us-gaap:InventoryWorkInProcess.

The official record: Tandem Diabetes Care’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tandem Diabetes Care's work in process.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Tandem Diabetes Care's work in process?: Tandem Diabetes Care (TNDM) reported work in process of $26.75M in Q1 2026.
How has Tandem Diabetes Care's work in process changed year-over-year?: Tandem Diabetes Care's work in process decreased by 25.0% year-over-year, from $35.67M to $26.75M.
What is the long-term trend for Tandem Diabetes Care's work in process?: Over 5 years (2020 to 2025), Tandem Diabetes Care's work in process has grown at a 8.7% compound annual growth rate (CAGR), from $15.66M to $23.81M.
What does work in process mean?: Partially completed goods currently in the manufacturing process, including materials, labor, and overhead costs incurred to date.